$599

Altimmune Ph2 Obesity and Ph1b T2DM Pemvidutide Data

Altimmune announced topline results from a Week 24 interim analysis of pemvidutide (QW GLP-1/GCG dual agonist) in its 48-week MOMENTUM Ph2 obesity trial (view CT.gov record) along with full results from the 12-week Ph1b safety trial in subjects with obesity or overweight and T2DM (view CT.gov record). The company hosted an associated investor call to discuss the results (webcast; slides). Of note, Altimmune stated it is on track to initiate a Ph3 obesity trial in H1 2023. Following the news, Altimmune’s stock price decreased approximately -54%. Below, FENIX provides highlights and insights, including thoughts on whether Altimmune will be able to differentiate pemvidutide from semaglutide, tirzepatide, and other dual agonists in development.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.